Standard treatment for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy, but more than half of all patients relapse within 3 years. Previous trials of ...

Patients with muscle-invasive bladder cancer who underwent whole pelvis radiation showed improved cancer-specific survival and overall survival.

Investigators assessed whether intravesical BCG is necessary for patients with high-grade T1 nonmuscle-invasive bladder cancer who have unremarkable histology on the second transurethral resection.

In a phase 1b trial, treatment of patients with muscle-invasive bladder cancer with intravesical oncolytic virus cretostimogene grenadenorepvec in combination with nivolumab was safe and led to ...

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that. The clinical ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

Huntsman Cancer Institute’s Urologic Cancers Program provides comprehensive, compassionate, state-of-the-art care for people with these cancers. Our experts treat and diagnose all types of urologic ...

In a phase 1 trial in patients with non-muscle invasive bladder cancer, Aura’s viruslike drug conjugate (VDC) bel-sar—along with infrared light activation—completely eradicated the tumors of ...

The two most common types are stress urinary incontinence, which may be caused by weakened pelvic floor muscles, and overactive bladder ... together with pelvic muscle exercises.

which is the muscle that lines the bladder. OAB and detrusor overactivity can both cause trouble with urination. With these conditions, you may have involuntary spasms in your bladder muscles ...

(Reuters) -Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the main goal in a confirmatory trial.